Clostridioides difficile Infection

Send stool testing when the patient has new-onset, unexplained diarrhea, operationalized as at least 3 unformed stools in 24 hours without an alternative etiology. Evaluate competing causes before attributing symptoms to CDI, particularly when diarrhea follows enteral feeding, laxatives, inflammatory bowel disease activity, ischemic colitis, other enteric infection, or medication exposure. fda+1fdaClinical Review Memo - VOWSTScienceDirectTrends in Clostridioides difficile diagnosis before and after a change in testing algorithm - ScienceDirect

Use the laboratory's multistep algorithm when available. A glutamate dehydrogenase assay with toxin A/B enzyme immunoassay, with nucleic acid amplification test (NAAT) adjudication of discordant specimens, links toxin detection to clinical disease more effectively than NAAT alone. NAAT is highly sensitive for toxigenic C. difficile but cannot distinguish colonization from infection and can drive unnecessary treatment when ordered in patients with low pretest probability. ScienceDirect+1ScienceDirectTrends in Clostridioides difficile diagnosis before and after a change in testing algorithm - ScienceDirectOxford AcademicToxin Enzyme Immunoassays Detect Clostridioides difficile ...

A toxin-negative, NAAT-positive result requires bedside reassessment rather than reflex treatment. Continue evaluating non-CDI causes if the stool frequency, abdominal findings, and clinical trajectory do not support toxin-mediated disease; toxin EIA added to molecular testing can help differentiate clinical disease from colonization. ScienceDirect+2ScienceDirectTrends in Clostridioides difficile diagnosis before and after a change in testing algorithm - ScienceDirectOxford AcademicS814 • OFID 2019:6 (Suppl 2) • Poster AbstractsOxford AcademicPediatric Clostridioides difficile Infection: Diagnosis and ...

At presentation and at least daily in hospitalized patients, assess volume status, blood pressure, abdominal distension and tenderness, stool output, and the possibility of ileus. Severe diarrhea can cause dehydration, electrolyte loss, kidney failure, and hypotension; CDI can progress to toxic megacolon, colonic rupture, peritonitis, septicemia, and death. fda+1fdaClinical Review Memo - VOWSTfdaREBYOTA

Classify disease as fulminant when hypotension or shock, ileus, or megacolon is present. These features matter because the fidaxomicin trials excluded fulminant disease, and guideline-directed treatment remains high-dose oral or nasogastric vancomycin rather than fidaxomicin. IDSAIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

Obtain urgent surgical input for suspected toxic megacolon, perforation, peritonitis, or clinical decline despite aggressive medical management. Colectomy may be required when medical therapy fails; do not defer consultation until perforation or refractory shock develops. fda+1fdaClinical Review Memo - VOWSTBMJClostridioides difficile-associated disease - Symptoms, diagnosis and treatment | BMJ Best Practice

For adults with an initial nonfulminant CDI episode, use fidaxomicin in preference to vancomycin when resources permit. IDSA/SHEA made this a conditional recommendation after randomized trial data showed lower recurrence with fidaxomicin; the guideline retains vancomycin as an acceptable alternative. IDSA+1IDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in AdultsIDSAClinician Management Preferences for Clostridioides difficile ...

Do not substitute fidaxomicin for the established fulminant CDI regimen. The focused guideline preserves vancomycin 500 mg orally or by nasogastric tube 4 times daily for fulminant disease because supporting fidaxomicin studies excluded this population. IDSAIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

Metronidazole has a limited role relative to fidaxomicin and vancomycin. Contemporary guidance and reviews describe fidaxomicin or oral vancomycin as preferred initial agents, with metronidazole reserved as an alternative in selected patients or settings rather than routine first-line therapy. BMJ+2BMJClostridioides difficile-associated disease - Symptoms, diagnosis and treatment | BMJ Best PracticeScienceDirectRecommendations and guidelines for the treatment of Clostridioides difficile infection in TaiwanIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

For a first recurrence, select fidaxomicin when feasible; a 10-day course or a tapered-and-pulsed fidaxomicin regimen may be used. Vancomycin given as a standard 10-day course or as a tapered-and-pulsed regimen remains an alternative, particularly when the prior episode was treated with a different agent or fidaxomicin is unavailable. fda+2fdaClinical Review Memo, November 30, 2022 - REBYOTAfdaREBYOTAIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

For multiple recurrences, avoid repeating identical short-course therapy without a prevention plan. Options described in guidance and FDA reviews include tapered-and-pulsed fidaxomicin or vancomycin, a vancomycin course followed by rifaximin, bezlotoxumab during antibacterial treatment for eligible high-risk adults, and microbiota-based therapy after antibacterial treatment. fda+2fdaClinical Review Memo, November 30, 2022 - REBYOTAfdaREBYOTAIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B and is indicated to reduce recurrence in adults receiving antibacterial treatment for CDI who are at high risk of recurrence. Consider it during the antibacterial treatment course rather than after another recurrence has already occurred, using patient-level recurrence risk and feasibility to guide use. fda+2fdaClinical Review Memo, November 30, 2022 - REBYOTAfdaREBYOTAIDSASHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults

Microbiota-based therapy is a recurrence-prevention intervention after completion of antibacterial treatment, not rescue therapy for untreated fulminant colitis. REBYOTA is fecal microbiota, live-jslm, and was licensed for prevention of recurrent CDI; VOWST studies and labeling materials similarly focus on prevention after clinical response to antibacterial treatment. fda+1fdaClinical Review Memo - VOWSTfdaREBYOTA

Track unformed stool frequency, ability to maintain oral intake, blood pressure, abdominal pain or distension, and renal and electrolyte consequences of diarrhea. A response after CDI therapy is reflected clinically by fewer than 3 unformed stools in 24 hours for at least 2 consecutive days in VOWST trial definitions; use stool trajectory together with overall clinical improvement rather than molecular positivity to judge response. fdafdaClinical Review Memo - VOWST

Do not use NAAT positivity alone as a treatment-response endpoint. Molecular tests detect toxigenic organisms and may remain positive despite resolution; repeat testing should be driven by recurrent compatible diarrhea, not by a desire to document eradication. ScienceDirect+1ScienceDirectTrends in Clostridioides difficile diagnosis before and after a change in testing algorithm - ScienceDirectOxford AcademicPediatric Clostridioides difficile Infection: Diagnosis and ...

At discharge, specify the completed CDI regimen, whether non-CDI antibiotics were stopped or narrowed, warning signs of fulminant colitis, and the recurrence-prevention plan. Patients with recurrent CDI account for substantial morbidity and prolonged hospital stays, so early follow-up should focus on recurrent diarrhea and antibiotic exposure rather than routine stool retesting. fdafdaREBYOTA